睡莲花提取物对小鼠实验性肝损伤的保护作用研究

目的:考察维药睡莲花提取物对小鼠肝损伤模型的保护作用。方法:采用D-氨基半乳糖(D-Ga IN)建立化学性肝损伤模型,卡介苗联合脂多糖(BCG+LPS)建立免疫性肝损伤模型,检测小鼠血清转氨酶水平,取肝脏称量质量,计算肝脏系数并检测肝组织匀浆中SOD、GSH-Px活性及NO、MDA含量。结果:在D-Ga IN致小鼠化学性肝损伤模型中,睡莲花提取物140 mg/kg可显著降低模型小鼠血清AST水平,280 mg/kg可显著降低模型小鼠血清ALT、AST水平,140、280 mg/kg均可使肝组织SOD、GSH-Px活性显著升高,280 mg/kg可使肝组织MDA含量显著降低,70、140、280 mg/kg均可使肝组织NO含量显著降低;在免疫性肝损伤模型中,睡莲花提取物280 mg/kg可显著降低模型小鼠血清ALT、AST水平,140、280 mg/kg均可显著降低肝损伤小鼠的肝脏系数;70、140、280 mg/kg均可使肝组织SOD、GSH-Px活性显著升高,MDA与NO含量显著降低。结论:睡莲花提取物对实验性肝损伤具有一定的保护作用,并具有抗氧化活性。

维药神香草聚酰胺树脂柱40%乙醇洗脱物的成分分析及其对哮喘小鼠炎症的改善作用

目的:对神香草40%乙醇洗脱物进行成分分析,并考察其对哮喘小鼠炎症的改善作用。方法:收集聚酰胺树脂柱40%乙醇洗脱物,采用高效液相色谱-高分辨率质谱技术对神香草40%乙醇洗脱物成分进行分析。将72只小鼠随机分为空白组(生理盐水)、模型组(生理盐水)、地塞米松组(阳性对照,1.6 mg/kg)和神香草40%乙醇洗脱物高、中、低剂量组(200、100、50 mg/kg),每组12只。除正常组外,其余各组小鼠均于实验第0、14天ip 0.2 m L卵白蛋白(OVA)致敏;于实验第25~31天ig给药,每天1次;给药结束后,用2 mg/mL OVA连续滴鼻激发7 d。末次滴鼻激发24 h后,检测各组小鼠肺泡灌洗液(BALF)中肿瘤坏死因子α(TNF-α)、白细胞介素4(IL-4)和干扰素(IFN-γ)水平;观察肺组织病理变化。结果:共鉴定出11种化合物,相对百分含量为40.89%,主要成分有迷迭香酸、木犀草素7-O-α-L-吡喃鼠李糖(1→6)-β-D-吡喃葡萄糖苷、金丝桃苷等。与空白组比较,模型组小鼠BALF中TNF-α、IL-4水平升高,IFN-γ水平降低,IL-4/IFN-γ比值增大(P<0.01);肺组织破坏严重,血管周围有炎症细胞浸润。与模型组比较,地塞米松组和神香草40%乙醇洗脱物高、中剂量组小鼠BALF中TNF-α、IL-4水平降低,IFN-γ水平升高,IL-4/IFN-γ比值减小(P<0.01);肺组织病理变化改善。结论:本研究建立的分析方法能够有效地分析神香草40%乙醇洗脱物中的化学成分;神香草40%乙醇洗脱物可调节哮喘小鼠肺组织炎症因子的释放,减轻哮喘小鼠肺组织的炎症病变。

Esculin alleviates acute kidney injury and inflammation induced by LPS in mice and its possible mechanism

Acute kidney injury(AKI)is a common clinical serious illness.Esculin(ES)is a coumarin compound of traditional Chinese medicine Cortex Fraxini.Our previous study has found that ES protects against inflammation and renal damage in diabetic rats.In the present study,we aimed to investigate the effects and the possible mechanism of ES against lipopolysaccharides(LPS)-induced AKI in mice.Renal morphology was observed by H&E staining.Renal function was evaluated by blood urea nitrogen(BUN)level and creatinine content in serum.Inflammatory factor levels were measured by ELISA assay.The inflammatory proteins were analyzed by RT-PCR and Western blotting analysis.The results showed that ES alleviated LPS-induced pathological injury and renal dysfunction,and decreased BUN level and creatinine content in serum.In addition,ES significantly reduced the release of pro-inflammatory factors,including IL-1β,IL-6 and TNF-α,chemokine MCP-1 and cell adhesion molecule ICAM-1.Furthermore,the expressions of inflammatory pathway proteins P2 X7,HMGB1,TLR4 and MyD88 both at the mRNA and protein levels were all down-regulated by ES in the kidney tissue of LPS-challenged mice.These results suggested ES protected against LPS-induced AKI through inhibiting P2 X7 expression and HMGB1/TLR4 inflammatory pathway.

Rapid and sensitive HPLC-MS/MS method for quantitative determination of isochlorogenic acid B in rat plasma and its application in pharmacokinetic study

A sensitive LC-ESI-MS/MS method for determination of isochlorogenic acid B in rat plasma was developed and validated in the present study. Plasma samples were prepared by a simple protein precipitation with methanol containing resveratrol as internal standard (IS). The chromatographic separation was performed on a Zorbax SB-Cjg column (3.5 pm, 2.1 mmx 100 mm, Agilent, USA) at a flow rate of 0.2 mL/min using methanol/water containing 0.1% formic acid (v/v) as mobile phase. The detection was performed on a triple quadrupole tandem mass spectrometer equipped with Electronic Spray Ion by selected reaction monitoring (SRM) of the transitions at m/z 515.3->352.9 for isochlorogenic acid B and m/z 227.1-143.1 for IS, respectively. The calibration curve of the method was linear over the range of 5-2500 ng/mL (r^2= 0.9982). The intra- and inter-day precisions (R.S.D.%) were less than 12.46%, and the accuracy (R.E.%) was within ±5.80%. Isochlorogenic acid B was sufficiently stable under all relevant analytical conditions. The validated method was successfully applied to the plasma pharmacokinetic studies of isochlorogenic acid B in rats. It was found that isochlorogenic acid B had non-linear pharmacokinetic characteristics in rats within the dosage ranges from 5 to 20 mg/kg.

Determination of deferasirox particle size distribution via laser diffraction and its application in establishing a correlation between particle size and drug dissolution in vitro

Deferasirox is the first-line drug for iron overload due to thalassemia in adults and pediatric patients. It is classified as a type II compound in the Biopharmaceutics Classification System, and thus the particle size of its active pharmaceutical ingredient(API) should be strictly controlled during the manufacturing process. In the present study, laser diffraction was adopted to measure the particle size distribution of deferasirox API. We also developed and validated an accurate and convenient method by investigating important optical parameters and sample dispersing conditions. The relative standard deviation values, namely, d(0.1), d(0.5), d(0.9), and d(4,3), measured via methodology validation and actual sample measurement were < 3%. The dissolution curves of several batches of dispersible tablets prepared using deferasirox with different particle sizes were compared in the four dissolved media to investigate the influence of particle size on drug dissolution in vitro. Results indicated that the particle size distribution of deferasirox API significantly affected the release of its dispersible tablet.

The synthesis and antibacterial activity evaluation of oxazolidinone-deferasirox conjugates

We reported herein the synthesis and antibacterial activity evaluation of two oxazolidinone-deferasirox conjugates with different linkers that were designed based on the“Trojan horse”strategy.The conjugates could combine with Fe^(3+)ions as the deferasirox.However,both conjugates were inactive against tested bacteria,including S.aureus,E.coli,A.baumannii,and P.aeruginosa.The results suggested that the synthesized iron chelator deferasirox was not suitable as a siderophore of the bacteria to transport the antibiotic,or the coupling linker of the synthesized conjugates could not be hydrolyzed to release the oxazolidinone in the cytoplasm.Therefore,the design and synthesis of oxazolidinone-deferasirox conjugates need further exploration.

Biocatalytic bis-C-alkylation of phenolics using one-pot cascades with promiscuous C-glycosyltransferase and prenyltransferase

C-glycosylation and C-prenylation are two important C-C-bond forming reactions for preparation,diversification and structural modification of natural/unnatural products with pharmacological activities.Here,we described unprecedented enzymatic cascades to C-glycosylate/prenylate different acyl resorcinol derivatives in stepwise,one-pot reactions by combining two promiscuous enzymes,MiCGT,a C-glycosyltransferase,and AtaPT,a prenyltransferase.Five novel bis-C-alkylated products were obtained and structurally identified by MS and NMR spectroscopic data as well as comparison with the literature.This study provided a potential synthetic strategy for synthesizing structurally novel and diverse compounds bearing both C-glycosyl and C-prenyl moieties by a two-step,enzymatic bis-C-alkylation.

Three new compounds from endophytic fungus Periconia sp.F-31

Three new compounds(1–3), including a chlorine-containing dihydroisocoumarin pericochlorosin A(1), a chlorinated phenol pericochlorosin B(2) and a decalin derivative pericoannosin G(3), were isolated from endophytic fungus Periconia sp. F-31 of the medicinal plant Annona muricata. The structures and absolute configurations were elucidated by extensive spectroscopic methods and calculated electronic circular dichroism analysis. Compound 2 displayed potent anti-HIV activity with IC50 value of 2.2 μM.